- Home
- IMNN vs APRE Comparison
IMNN vs APRE Comparison
Compare IMNN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- APRE
- Stock Information
- Founded
- IMNN 1982
- APRE 2006
- Country
- IMNN United States
- APRE United States
- Employees
- IMNN N/A
- APRE N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMNN Health Care
- APRE Health Care
- Exchange
- IMNN Nasdaq
- APRE Nasdaq
- Market Cap
- IMNN 12.1M
- APRE 10.0M
- IPO Year
- IMNN 1985
- APRE 2019
- Fundamental
- Price
- IMNN $0.77
- APRE $1.80
- Analyst Decision
- IMNN Buy
- APRE Strong Buy
- Analyst Count
- IMNN 2
- APRE 2
- Target Price
- IMNN $14.00
- APRE $15.50
- AVG Volume (30 Days)
- IMNN 2.3M
- APRE 50.9K
- Earning Date
- IMNN 08-13-2025
- APRE 08-11-2025
- Dividend Yield
- IMNN N/A
- APRE N/A
- EPS Growth
- IMNN N/A
- APRE N/A
- EPS
- IMNN N/A
- APRE N/A
- Revenue
- IMNN N/A
- APRE $1,284,475.00
- Revenue This Year
- IMNN N/A
- APRE N/A
- Revenue Next Year
- IMNN N/A
- APRE N/A
- P/E Ratio
- IMNN N/A
- APRE N/A
- Revenue Growth
- IMNN N/A
- APRE 33.27
- 52 Week Low
- IMNN $0.37
- APRE $1.41
- 52 Week High
- IMNN $3.65
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- IMNN 40.86
- APRE 49.58
- Support Level
- IMNN $0.70
- APRE $1.64
- Resistance Level
- IMNN $0.86
- APRE $1.81
- Average True Range (ATR)
- IMNN 0.10
- APRE 0.15
- MACD
- IMNN -0.05
- APRE -0.01
- Stochastic Oscillator
- IMNN 10.34
- APRE 51.76
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.